What commercial agreement did Mayne Pharma Group (ASX:MYX) recently announce?

Mayne Pharma Group (ASX:MYX) announced that its wholly-owned subsidiary, DistributerRx, has entered into an exclusive partnership with Atlanta-based Resilia Pharmaceuticals.

What is RECEDO topical gel, and why is it important to this deal?

RECEDO is a prescription-grade scar management and wound healing agent widely recommended in the American healthcare market. It is specifically used to treat old and new hypertrophic or keloid scarring from burns, general surgeries, and trauma wounds.

How will Mayne Pharma Group (ASX:MYX) generate revenue from this distribution partnership?

DistributerRx will receive a structured fixed fee for each RECEDO prescription filled through its digital distribution platform. This transactional model is designed to provide a predictable revenue stream per unit volume while keeping outcomes cost-effective for patients and prescribers.

What is management's strategic goal for Mayne Pharma's DistributerRx platform?

Management is aiming to commercialise and scale its digital prescription distribution infrastructure by onboarding third-party pharmaceutical products.

Which specific medical sectors are being targeted for commercial expansion?

The commercial expansion plans will intensely target high-demand medical sectors across the United States, specifically plastic surgery and OB/GYN practices.

Image for illustrative purposes only. Not a real photo.

Mayne Pharma secures exclusive US distribution partnership

Written by Jon CuthbertPublished Jun. 1 2026Last Updated Jun. 1 2026

Mayne Pharma Group (ASX:MYX) announced that its wholly-owned subsidiary, DistributerRx, has secured its inaugural third-party commercial partnership through an exclusive agreement with Atlanta-based Resilia Pharmaceuticals.

Under the precise terms of the distribution deal, DistributerRx will utilise its streamlined digital prescription distribution platform to oversee the exclusive United States distribution of RECEDO topical gel.

RECEDO is currently recognised as one of the most widely recommended, prescription-grade scar management and wound healing agents in the American healthcare market, specifically indicated for treating old and new hypertrophic or keloid scarring resulting from burns, general surgical procedures, and trauma wounds.

In exchange for leveraging the unique and scalable infrastructure, DistributerRx is set to receive a structured fixed fee for each prescription filled, delivering a highly cost-effective outcome for the product, prescribers, and patients.

The alliance represents a pivotal step in Resilia’s overarching corporate strategy to expand RECEDO’s adoption among specialist healthcare prescribers across the country.

Commercial expansion plans will intensely target high-demand medical sectors, particularly specialists within plastic surgery—including those performing complex Mohs surgery procedures—and OB/GYN practices focusing on post-Caesarean section recovery treatments.

By combining Mayne Pharma’s digital infrastructure with Resilia’s proven therapeutic profile, the partnership addresses historic market shortfalls in advanced scar care.

Executives from both companies expressed strong confidence that this mutually beneficial relationship will accelerate commercial reach.

At the time of reporting, Mayne Pharma’s share price was $2.36.